Advanced and metastatic prostate cancer: ESMO Clinical . . . This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
Metastatic castration-resistant prostate cancer (mCRPC) Metastatic prostate cancer happens when the cancer spreads from the prostate to other parts of the body Sometimes the cancer spreads and hormone therapy helps control it This is called metastatic castration-sensitive prostate cancer (mCSPC) If the cancer spreads and no longer responds to hormone therapy medicines, it's considered mCRPC
TALZENNA Plus XTANDI Significantly Improves Radiographic . . . Prostate cancer is the second most common cancer in men worldwide, with an estimated 1 4 million new cases diagnosed globally in 2022 1 and 330,000 new cases anticipated in the United States in 2026 2 mCSPC, is a form of advanced prostate cancer that has spread beyond the prostate but is still sensitive to androgen inhibition 3 Despite recent
CUA Call-to-Action: Advanced Prostate Cancer (mCSPC) – 2026 . . . Apply the latest guideline recommendations and evidence to optimize disease characterization and treatment selection in mCSPC Integrate advanced imaging, biomarker, and genetic testing into clinical decision-making to personalize therapy
Advanced and metastatic prostate cancer: ESMO Clinical . . . This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
Prostate Cancer, Version 3 - jnccn. org For patients with mCSPC, disease characteristics, such as whether metastases arose synchronously or metachronously and the degree of metastatic burden, impact therapy decisions, including how much treatment intensification is appropriate and when prostate-directed and or metastasis-directed therapy should be considered
Advanced Prostate Cancer - HealthUnlocked Treatment with apalutamide (Erleada) induced a deeper and earlier prostate-specific antigen (PSA) response compared with enzalutamide (Xtandi) in androgen receptor synthesis inhibitor-naive patients with metastatic castration-sensitive prostate cancer (mCSPC), according to findings from a real-world study 1 A deep PSA response, defined as a ≥90% PSA decline (PSA90), is a critical treatment
Metastatic Castration-Sensitive Prostate Cancer: Optimizing . . . Further incremental progress in the outcome of patients with mCSPC came from the addition of novel agents, docetaxel or abiraterone, to ADT for more aggressive up-front treatment of metastatic prostate cancer
